Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

To main content To sitemap To news Check availability details

Preclinical evaluation of autologous NK cells for the treatment of HCC.

Reference number
Coordinator XNK Therapeutics AB
Funding from Vinnova SEK 289 949
Project duration September 2023 - June 2025
Status Ongoing
Venture Competence centre

Last updated 5 November 2025

Reference number 2023-02032